AOD 9604 10mg Research Peptide

AOD 9604 10mg is a synthetic growth hormone–derived research peptide corresponding to the C-terminal fragment 176–191 of human growth hormone. Commonly referred to as GH Fragment 176–191, AOD 9604 was engineered to study lipolytic and fat metabolism–related signaling pathways without stimulating insulin-like growth factor 1 production. Supplied as a lyophilized powder with a reported purity greater than 99%, AOD 9604 10mg is intended exclusively for laboratory research use.

What Is AOD 9604 10mg?

AOD 9604 10mg is a modified fragment of human growth hormone designed to isolate the fat metabolism–associated activity of growth hormone while minimizing anabolic and mitogenic effects observed with the full-length hormone. To improve molecular stability, the peptide includes a tyrosine substitution at the N-terminus, enhancing resistance to enzymatic degradation in experimental models.

AOD 9604 10mg is an experimental research compound and is not approved for human or animal use.

Research Background

Human growth hormone contains multiple functional regions, each associated with different biological actions. Research has identified that:

• The N-terminal region is associated with insulin-related signaling

• Amino acids 108–129 demonstrate mitogenic activity

• The 176–191 fragment is linked to lipolytic and fat metabolism signaling

AOD 9604 was developed in the 1990s to allow researchers to study the lipolytic properties of growth hormone without activating growth-related or insulin-mediated pathways. Preclinical research continues to explore its role in fat metabolism and energy balance signaling. All findings remain preclinical.

Mechanisms of Research Interest

Lipolytic Pathway Research

AOD 9604 10mg is studied for its potential involvement in lipolysis, the biochemical process by which stored triglycerides are broken down into glycerol and free fatty acids.

Beta-Adrenergic Receptor Signaling

Animal studies suggest AOD 9604 exposure may increase beta-3 adrenergic receptor gene expression in adipose tissue, potentially enhancing responsiveness to lipolytic signaling pathways.

IGF-1–Independent Activity

Unlike full-length growth hormone, AOD 9604 appears to act independently of insulin-like growth factor 1 stimulation, allowing focused investigation of fat metabolism mechanisms without anabolic signaling.

Energy Balance Research

Experimental models explore AOD 9604 for its potential role in regulating energy utilization and adipose tissue signaling under metabolic stress conditions.

All mechanisms described are experimental observations or theoretical models and do not imply clinical or therapeutic benefit.

Molecular and Chemical Information

• Product Name: AOD 9604 10mg

• Form: Lyophilized powder

• Purity: Greater than 99%

• Peptide Length: 16 amino acids

• Classification: Growth hormone fragment peptide

• Molecular Formula: C78H123N23O23S2

• Molecular Weight: 1815.12 g/mol

• Alternate Names: GH Fragment 176–191, Tyr-hGH Fragment 177–191

Research Applications

AOD 9604 10mg may be utilized by qualified researchers in laboratory investigations involving:

• Lipolysis and fat metabolism pathway research

• Beta-adrenergic receptor signaling studies

• Energy balance and adipose tissue research

• Growth hormone fragment activity analysis

All use must remain within controlled laboratory environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety, dosing, or efficacy data